Major Events

2020 / 01

Efficient Pharma Management Corp. has completed its recent restructuring effort. The change is made for the purpose of promoting faster business development and sharing the achievements with our investors and employees.

2018 / 03

Dr. Shen joins EffPha Team as the President and CEO. With his extensive drug development experience as well as his expertise in Data and Statistical Sciences, he leads EffPha into a new era and provides clients with a complete and integrated drug development and clinical study service portfolio.

2015 / 03

In order to meet client’s need for clinical study service, EffPha officially establishes a Clinical Operation Team. EffPha can now provide one-stop services from the planning of drug development, pre-clinical study management and regulatory submission to clinical operation and monitoring.

2013 / 04

EffPha successfully completes the US FDA e-submission test, and obtains approval from the US FDA. EffPha establishes the ability to submit regulatory packages in eCTD format prior to other local CROs.

2011 / 08

EffPha and Formosa Laboratories, Inc. enter a strategic alliance and founded TaiRx, Inc. The development rights obtained from China Medical University for new anti-cancer drugs is transferred to TaiRx.

2010 / 03

EffPha signs a technology transfer agreement (CHM-2133-P) with China Medical University to obtain the development rights of new drug for cancers, including breast cancer, colon cancer and liver cancer.

2010 / 01

EffPha officially sets up an office in Nankang Business Park to provide high quality drug development project management, consulting and regulatory submission services.

2009 / 10

Efficient Pharma Management Corp. is founded in 2009 by Dr. Du-Shieng Chien and Dr. Yi-Wen Chu. They create a scientific consulting team composed of regulatory, CMC, toxicology, pharmacokinetics, data management and statistical experts that have more than 20-30 years of experience working in international pharmaceutical companies.